 |
|
| |
| WEBINAR: |
| |
Leveraging Key Biomarkers to Advance
Immuno-Oncology Drug Development and Find the Right Trial Participants |
| |
| Wednesday, March 7 | 11 a.m. ET |
| |
| Register Now > |
| |
|
 |
|
| Oncology drug development is in a period of unprecedented innovation, led by the discovery and utilization of predictive biomarkers to facilitate patient selection and, ultimately, better outcomes and accelerated timelines. |
| |
| Join us for an in-depth webinar that addresses immunotherapy development options and implications for drug developers, such as: |
| |
- Factors driving the importance of biomarkers in immuno-oncology development
- How to leverage key technologies – flow cytometry, immunohistochemistry and next-generation sequencing
- A real-world example of how to tackle the challenge of effective patient recruitment
- The best way to engage a CRO / lab partner and access biomarker assays, solutions and disease state expertise
|
| |
| Presented by: |
| |
 |
Steven M. Anderson, PhD
Chief Scientific Officer
Covance |
|
 |
Suso Platero, PhD
Global Leader, Precision Medicine
Covance |
|
|
| |
|
| |
| COMING SOON: |
| |
| Flexible, Efficient, Risk Mitigating: The Expanding Role of Single Site PMA in CDx Development |
| |
| Wednesday, March 21 | 11 a.m. ET |
| |
| Register Now > |
| |
| |
|
| |
| |
|
|
| |
| Covance Inc., headquartered in Princeton, NJ, USA, is the drug development
business of Laboratory Corporation of America Holdings (LabCorp).
COVANCE is a registered trademark and the marketing name for Covance Inc.
and its subsidiaries around the world. |
| |
For more information about Covance, visit us online at www.covance.com.
Copyright ©2018 Covance Inc. All rights reserved. |
| |
Covance Inc., 210 Carnegie Center Princeton, NJ 08540-6233 USA
THE AMERICAS: +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
EUROPE/AFRICA: +00.800.2682.2682 +44.1423.500888
ASIA PACIFIC: +800.6568.3000 +65.6.5686588 |
| |
| |
|
|
|
